Searched for
DRUGMAKER LUPIN
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Zydus partners with Lupin to co-market generic semaglutide in IndiaZydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide ...
- Lupin clears Mirabegron patent dispute with Astellas in $90 million deal, secures US sales continuityDrugmaker Lupin has settled a patent infringement dispute with Astellas Pharma over its Mirabegron product for $90 million. The agreement i...
- Sun Pharma, Lupin recall drugs in US market: USFDASun Pharmaceutical is recalling the affected lot that was produced at the drugmaker's Dadra-based facility. The company is recalling the lo...
- Lupin Q3 Results: Net profit up 24% at Rs 545 crThe Mumbai-based drugmaker had reported a net profit of Rs 438.3 crore in the October-December quarter of the previous fiscal.
- Lupin, TB Alliance join hands for new therapy for drug-resistant tuberculosisTB Alliance President and CEO Mel Spigelman said that partnering with Lupin -- a well-established manufacturer with experience delivering h...
- Lupin gets USFDA nod for generic drugDrugmaker Lupin on Friday said it has received approval from the US health regulator to market Droxidopa capsules, used to treat dizziness....
- Lupin shuts manufacturing drug plant after 17 employees test positive for Covid-19The company has some 11 manufacturing plants at the Ankleshwar site in Gujarat state, which is spread out over 40 acres and has 984 employe...
- Lupin remains a ‘sell’ on Q4 miss; Target prices cutCitigroup and Elara have maintained sell rating and Antique has reiterated its hold rating.
- Lupin launches generic hypertension drug in USLupin's tablets for treating hypertension, Amlodipine and Valsartan, are the generic version of Novartis's Exforge tablets.
- Lupin to acquire additional 40% stake in SA's Pharma DynamicsThe move would add an additional global muscle to Pharma Dynamics' operations and support the next phase of growth for the company, he adde...
- TCS, Lupin rise in CLSA portfolio, State Bank of India outCLSA has tweaked its model portfolio, increasing the weightage of India’s leading software exporter TCS and domestic drugmaker Lupin.
- Billionaire Jhunjhunwala sells holding worth over Rs 300 cr in Q1Shares of drugmaker Lupin fell after the company disclosed that billionaire investor Rakesh Jhunjhunwala has hal-ved his stake in the compa...
- Lupin files second suit against RanbaxyMumbai-based drugmaker Lupin has filed a second suit in the US against Ranbaxy Laboratories to prevent the country’s largest drugmaker from...
- Novo sues Lupin to block generic in USDanish company Novo Nordisk has sued Mumbai-based drugmaker Lupin to prevent it from launching the low priced version of its patented diabe...
- Lupin can't sell pill in US, Teva files patent suitIsraeli drugmaker Teva Pharma has filed a patent infringement suit in the US against Lupin that prevents the Indian pharma company from sel...
- Lupin settles case with WyethLupin has struck an out-of-court settlement with Wyeth relating to the foreign company’s antidepressant ‘Effexor XR’ capsules.
Load More
